From baseline to 1 year, the Ki-67 index decreased in the dietary intervention cohort by 15% and increased in the control cohort by 24%. “If approved, this approach has the potential to transform the ...

“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says ...

Ferring has announced the opening of the first clinical trial sites for 2 studies within the ABLE clinical trial program as well as the launch of the phase 1/2 LUNAR trial. “The combination of ...

"If a practice has determined in writing that there are insurers whose policies advised that they will not accept this code, it seems reasonable not to report that code to that insurer even when ...

Lenvatinib/pembrolizumab and nivolumab/cabozantinib show improved survival and response rates in advanced renal cell carcinoma. Machine learning and surgical algorithms are advancing personalized ...

“These types of technologies can really make office urology much more efficient, which I think is very, very promising and one of the most promising areas in artificial intelligence,” says Chad ...

A race coefficient improves 4Kscore calibration for Black men, enhancing prostate cancer risk assessment accuracy. Increasing diversity in clinical trials is crucial for more representative prostate ...

“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says ...

FDA approval of N-803 represents a significant advancement in immunotherapy for BCG-unresponsive NMIBC. Blue light cystoscopy improves clinical outcomes compared to white light cystoscopy in NMIBC ...

As the year comes to a close, we revisit some of this year’s top content on the management of renal cancer.

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter.

"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.